Get Plus

Sign in to baba News

One account across the web, iPhone and Android — your subscription follows it.

or use an email code

Search stories

Type at least two characters. Results come from every newsroom baba reads.

↑↓ to move · ↵ to open · esc to close

Sign in to baba News

Sign in to keep asking. News Plus removes the daily limit.

or use an email code

Ongoing Story· Day 2

New Schizophrenia Drug Offers Hope But Remains Out of Reach for Many

4 developments

YnetHealth

New Schizophrenia Drug Faces Affordability Barrier in Israel

Translated & summarized from Ynet by baba

CenterCharged tone

Hebrew · 1 newsroom

A new schizophrenia drug, Cobenfy, approved by the FDA, offers a novel treatment with potentially fewer side effects but comes with a high private cost of approximately 8,000 shekels per package in Israel. Families and mental health advocates are pushing for its inclusion in the national health basket, citing the financial burden on vulnerable patients and the underfunding of mental health services. Experts highlight the drug's potential benefits and the broader challenges in accessing advanced psychiatric treatments within Israel's healthcare system.

The story in 5 lines · by baba

  • New schizophrenia drug Cobenfy faces accessibility issues in Israel due to its high cost.
  • Cobenfy offers a novel treatment mechanism with potentially fewer side effects than older drugs.
  • The drug's private cost is approximately 8,000 shekels per package, unaffordable for many patients.
  • Mental health advocates are calling for Cobenfy's inclusion in Israel's national health basket.
  • Experts cite underfunding of mental health services as a barrier to accessing new treatments.

A new schizophrenia medication, Cobenfy, approved by the US FDA, offers a novel treatment approach by not directly blocking dopamine receptors, unlike older antipsychotics. This mechanism aims to reduce side effects such as weight gain, tremors, and excessive salivation, which have plagued patients on existing treatments. However, the high cost of Cobenfy, approximately 8,000 shekels per package for private funding, presents a significant obstacle to accessibility for many patients and their families in Israel.

Yoki, a mother whose son has lived with schizophrenia for nearly 30 years, shared her family's arduous journey, highlighting the severe impact of the illness and the limitations of current treatments. She emphasized that many individuals with mental illness are among the most vulnerable and impoverished populations, relying on disability stipends that cannot cover the drug's cost. While some limited funding options exist, they do not ensure broad access.

Psychiatrists, including Dr. Yoav Domani, acknowledge Cobenfy's potential to improve patient outcomes by targeting dopamine regulation differently. Dr. Domani explained that the drug works upstream to balance dopamine release, potentially mitigating side effects that affect motor function, motivation, and pleasure. Clinical trials showed a significant reduction in schizophrenia symptoms with Cobenfy compared to a placebo, with fewer adverse effects like weight gain or movement disorders, though gastrointestinal issues like nausea and constipation were noted.

Despite its promise, Cobenfy is still awaiting inclusion in Israel's national health basket, a process that has seen limited innovation in psychiatric treatments. Dr. Marina Kopchik, chairwoman of the Israeli Psychiatric Association, noted that only nine psychiatric drugs and technologies were submitted for inclusion this year, compared to dozens in other fields. She stressed that effective treatment for severe mental illness is life-saving and that the stigma surrounding mental health may contribute to underfunding and lower priority in resource allocation.

Experts like Gadi Rosenthal, chairman of the Mental Health Families Association, point to a broader issue of underfunding in Israel's mental health system, which receives a significantly smaller portion of the national health budget compared to other developed countries. This underfunding affects all aspects of care, from inpatient facilities to community services, and impacts the inclusion of new, potentially life-changing medications like Cobenfy. The association advocates for Cobenfy's inclusion in the health basket, arguing that the cost of not providing advanced treatments is ultimately borne by the public hospital system and struggling families.

YnetCentre · Rishon LeZion

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

HealthTopic

Sign in to baba News

Sign in to follow newsrooms, topics and people.

or use an email code

Mentioned

Related stories · 1

Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.

Open the Wire